. Author manuscript; available in PMC: 2016 Dec 7.

Published in final edited form as: Clin Cancer Res. 2014 Jun 26;20(17):4540–4548. doi: 10.1158/1078-0432.CCR-13-3231

Table 2. Summary evolved clonotypes in pre-treatment clonal IGH CDR3 sequences.

Clonal IGH CDR3 sequences were identified in nearly all patients as either complete V-DJ or incomplete D-J rearrangements. Among the 91 patients in which a complete V-DJ rearrangement was observed, the number of clones due to ongoing IGH evolution by V_H replacement at diagnosis is indicated, as well as the proportion of total clone size (major clone plus all evolved clonotypes) accounted for by these V_H-replaced clones. We used the definition of an evolved IGH clonotype initially proposed by Gawad et al. (12).

	N (percentage)	Mean, median (range)
No VDJ clone	7/98 (7.1%)	-

Pre-treatment VDJ clone identified	91/98 (92.9%)	-

No evidence of evolved clonotypes	6/91 (6.6%)	-

Evidence of evolved clonotypes	85/91 (93.4%)	-

Number of evolved clonotypes		Mean 195, median 22, (range 1 to 1,953)

Proportion of evolved clonotypes of total clone		Mean 3.4%, median 0.4%, (range 0.0010% to 59.8%)